Сорафениб-индуцированный тиреоидит у больной с рецидивом острого миеломонобластного лейкоза с мутацией FLT3-ITD - Журнал Терапевтический архив № 8 Вопросы лечения 2019
Сорафениб-индуцированный тиреоидит у больной с рецидивом острого миеломонобластного лейкоза с мутацией FLT3-ITD
Бальжанова Я.Б., Паровичникова Е.Н., Соколов А.Н. и др. Сорафениб-индуцированный тиреоидит у больной с рецидивом острого миеломонобластного лейкоза с мутацией FLT3-ITD. Терапевтический архив. 2019; 91 (8): 93–97. DOI: 10.26442/00403660.2019.08.000381
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В последние годы сорафениб используется для улучшения результатов терапии острых миелоидных лейкозов, протекающих с мутацией FLT3-ITD. Однако применение сорафениба в сочетании с цитостатическими препаратами может быть ассоциировано с высокой частотой нежелательных явлений. Нами представлен клинический случай тяжелого тиреоидита, развившегося в результате лечения сорафенибом у больной с рецидивом острого миеломонобластного лейкоза.
Ключевые слова: сорафениб, тиреоидит, острый миелоидный лейкоз, рецидив, мутация FLT3-ITD.
Keywords: sorafenib, thyroiditis, acute myeloid leukemia, relapse, FLT3-ITD mutation.
Ключевые слова: сорафениб, тиреоидит, острый миелоидный лейкоз, рецидив, мутация FLT3-ITD.
________________________________________________
Keywords: sorafenib, thyroiditis, acute myeloid leukemia, relapse, FLT3-ITD mutation.
Список литературы
1. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, de Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Nat Comprehens Cancer Network. 2017;15(7):926-57. doi: 10.6004/jnccn.2017.0116
2. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169
3. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195
4. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359
6. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974
7. Румянцев П.О. Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015;11(2):25-32 [Rumyantsev PO. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Klinicheskaja i Eksperimentalnaja Tireoidologija. 2015;11(2):25-32 (In Russ.)]. doi: 10.14341/ket2015225-32
8. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007
9. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, de Angelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053
10. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9
11. Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461
12. Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3 [Yusupova RA, Podolskaya TB. Ultrasonic investigation of the autoimmune thyroiditis in out-patient conditions. Prakticheskaja Medicina. 2017;(2):130-3 (In Russ.)].
13. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021
14. Van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234
15. Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib – quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936
16. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID:20825302
17. Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL, Huang H. Sorafenib-induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication-mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831
18. Mooij CF, Netea-Maier RT, ten Broek R, Gotthardt M, Hagleitner MM. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869
19. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y
2. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169
3. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195
4. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359
6. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974
7. [Rumyantsev PO. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Klinicheskaja i Eksperimentalnaja Tireoidologija. 2015;11(2):25-32 (In Russ.)]. doi: 10.14341/ket2015225-32
8. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007
9. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, de Angelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053
10. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9
11. Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461
12. Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3 [Yusupova RA, Podolskaya TB. Ultrasonic investigation of the autoimmune thyroiditis in out-patient conditions. Prakticheskaja Medicina. 2017;(2):130-3 (In Russ.)].
13. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021
14. Van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234
15. Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib – quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936
16. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID:20825302
17. Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL, Huang H. Sorafenib-induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication-mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831
18. Mooij CF, Netea-Maier RT, ten Broek R, Gotthardt M, Hagleitner MM. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869
19. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y
2. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169
3. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195
4. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359
6. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974
7. Румянцев П.О. Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015;11(2):25-32 [Rumyantsev PO. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Klinicheskaja i Eksperimentalnaja Tireoidologija. 2015;11(2):25-32 (In Russ.)]. doi: 10.14341/ket2015225-32
8. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007
9. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, de Angelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053
10. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9
11. Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461
12. Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3 [Yusupova RA, Podolskaya TB. Ultrasonic investigation of the autoimmune thyroiditis in out-patient conditions. Prakticheskaja Medicina. 2017;(2):130-3 (In Russ.)].
13. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021
14. Van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234
15. Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib – quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936
16. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID:20825302
17. Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL, Huang H. Sorafenib-induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication-mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831
18. Mooij CF, Netea-Maier RT, ten Broek R, Gotthardt M, Hagleitner MM. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869
19. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y
________________________________________________
2. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169
3. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195
4. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359
6. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974
7. [Rumyantsev PO. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Klinicheskaja i Eksperimentalnaja Tireoidologija. 2015;11(2):25-32 (In Russ.)]. doi: 10.14341/ket2015225-32
8. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007
9. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, de Angelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053
10. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9
11. Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461
12. Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3 [Yusupova RA, Podolskaya TB. Ultrasonic investigation of the autoimmune thyroiditis in out-patient conditions. Prakticheskaja Medicina. 2017;(2):130-3 (In Russ.)].
13. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021
14. Van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234
15. Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib – quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936
16. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID:20825302
17. Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL, Huang H. Sorafenib-induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication-mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831
18. Mooij CF, Netea-Maier RT, ten Broek R, Gotthardt M, Hagleitner MM. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869
19. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y
Авторы
Я.Б. Бальжанова, Е.Н. Паровичникова, А.Н. Соколов, В.В. Рыжко, М.А. Самцова, Е.О. Грибанова
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
National Research Center for Hematology, Moscow, Russia
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
________________________________________________
National Research Center for Hematology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.